

=> d his

(FILE 'HOME' ENTERED AT 13:14:49 ON 06 DEC 2007)

FILE 'REGISTRY' ENTERED AT 13:14:57 ON 06 DEC 2007

L1 STRUCTURE UPLOADED

L2 40 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:15:18 ON 06 DEC 2007


L3 1 S L2

FILE 'REGISTRY' ENTERED AT 13:15:34 ON 06 DEC 2007



=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.



chain nodes :

1 2 3 4 5 7 8 16 17 18

ring nodes :

9 10 11 12 13 14

chain bonds :

1-2 1-3 1-4 1-5 4-7 7-8 7-9 12-16 16-17 17-18

ring bonds :

9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

1-2 1-3 1-4 1-5 4-7 7-8 7-9 9-10 9-14 10-11 11-12 12-13 12-16 13-14 16-17 17-18

isolated ring systems :

containing 9 :

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 16:CLASS 17:Atom 18:CLASS

Generic attributes :

5:

Saturation : Unsaturated

Number of Carbon Atoms : 7 or more

Type of Ring System : Polycyclic

17:

Saturation : Unsaturated

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :

Node 5: Limited

C,C10

Node 17: Limited

N,N1

S,S1

C,C3

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:300422 CAPLUS
 DN 142:373822
 TI Preparation of thiazoline derivatives as FXa inhibitors
 IN Kubo, Keiji; Kuroita, Takanobu; Kawamura, Masaki; Sakamoto, Hiroki
 PA Takeda Pharmaceutical Company Limited, Japan
 SO PCT Int. Appl., 192 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030740	A1	20050407	WO 2004-JP14685	20040929
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1669352	A1	20060614	EP 2004-773616	20040929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2005126428	A	20050519	JP 2004-288257	20040930
	US 2007010528	A1	20070111	US 2006-574048	20060512
PRAI	JP 2003-341430	A	20030930		
	WO 2004-JP14685	W	20040929		
OS	MARPAT 142:373822				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted cyclic hydrocarbon group, (un)substituted heterocyclic group; X = bond, (un)substituted divalent chain hydrocarbon group; X' = bond, NR5; R5 = H, (un)substituted hydrocarbon group, etc.; Y = (un)substituted divalent hydrocarbon group; Y' = bond, carbonyl; ring A = (un)substituted nitrogenous heterocycle; Z1, Z3 = bond, (un)substituted divalent chain hydrocarbon group; Z2 = bond, NR6; R6 = H, (un)substituted hydrocarbon group, etc.; a = 0-2; ring B = II, etc.; R2 = H, halo, etc.; R3 = H, (un)substituted hydrocarbon group, etc.; R4 = (un)substituted hydrocarbon group; further details on R2, R3, R4 were provided.] were prepared For example, reaction of 1-(3-((6-chloro-2-naphthyl)sulfonyl)propionyl)piperazine, e.g., prepared from 1-piperazinecarboxylic acid tert-Bu ester, with 4-chloromethyl-1,3-thiazole-2-amine·2HCl followed by treatment with iodomethane afforded compound III·2HCl. In FXa (blood coagulation factor Xa) inhibition assays, the IC50 value of compound III·2HCl was 22 nM. Compds. I are claimed useful for the treatment of myocardial infarction, obstructive arteriosclerosis, etc. Formulations are given.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT